Creating and Restoring Volume in Patients with Chin Retrusion Using an Innovative Hyaluronic Acid Filler

Chantal Sciuto, MD; Maurizio Cavallini, MD; and Dario Bertossi, MD

1 Private Practice, Rome, Italy; 2 Unit of Dermatology & Dermaturosurgery, CDI Hospital, Milan, Italy; 3 Department of Maxillofacial Surgery, G.B. Rossi Hospital, University of Verona, Verona, Italy

BACKGROUND

- The projection and prominence of the chin and jawline are important aesthetic components that influence facial balance and harmony, especially of the profile. Inadequate chin projection may be considered unattractive or indicative of a weak personality.
- There are various reasons for deficiency of chin projection, including genetics and aging.
- Treating the chin and jaw region with hyaluronic acid (HA) is a noninvasive alternative to surgical correction, with the advantages of minimal risk and little to no downtime.
- VYC-25L (Allergan plc, Dublin, Ireland) is a novel HA-based filler for restoring and creating volume in the face. VYC-25L was specifically designed for, and has been studied in, the chin and jawline.
- VYC-25L was developed using Vycross technology (Allergan), formulated using both high- and low-molecular-weight HA, with a unique cross-linking feature.

PURPOSE

- The aim of this study was to assess the clinical benefit of VYC-25L as initial treatment to define the chin and jawline.

METHODS

- Fifteen adults with chin retrusion were treated in the chin and jawline (if required), using VYC-25L.
- Exclusion criteria were metabolic disorders, collagen anormolies, autoimmune diseases, scarring, ongoing dental treatment, and previous facial reconstruction due to trauma or resection. Also excluded were women who were pregnant or breastfeeding.
- The specific injection sites and quantity of VYC-25L were determined from clinical evaluation and were individualized for each patient.
- VYC-25L was injected into the subcutaneous and/or supraperiosteal space, depending on the area being treated.
- The revolutionary MD Codes approach was utilized to guide the injections (Figure 1). The chin region included the pogonion, mentum, sublabial crease, and both pre-jowl sulci. The jawline region included the mandibular border as well as the mandibular angle.
- Clinical photographs were obtained at baseline (before treatment) and immediately after treatment. Results were assessed by comparing pre- and post-treatment photographs and by clinical evaluation 1 month after treatment.

RESULTS

- All 15 patients (age range, 20-65 years) reported visible improvement from baseline in chin projection and lower face definition.
- The average quantity of VYC-25L per patient was 3.2 mL:
  - Jawline: range of 1.0 to 2.0 mL
  - Chin: range of 1.0 to 2.5 mL
- The achieved projection is best appreciated from the lateral (profile) view. Representative pre- and post-treatment images appear in Figures 2-4.
- No immediate/early serious adverse events occurred. Due to the short duration of the study, late complications (beyond 4 weeks post-treatment) have not been reported.

CONCLUSIONS

- Treatment of the chin and jawline with VYC-25L has proven safe, effective, repeatable, predictable, and well tolerated. Moreover, considering the preceding clinical data, a lengthy duration of the effect is expected (up to 24 months).
- Overall, the aesthetic results have been fully concordant with patients’ expectations.
- The favorable characteristics of VYC-25L, as well as the successful preliminary findings, make this treatment a viable noninvasive option to increase volume and improve definition in the chin and jawline.

REFERENCES


ACKNOWLEDGMENTS

The authors thank Lynda Seminara, CMP, of ClearView Medical Communications, LLC, Waltham, MA, USA for editorial assistance, funded by Allergan, plc at the request of the investigators. No payments were made to the authors.

Dr. Sciuto is a specialist in dermatology and aesthetic dermatology, in private practice in Rome. Disclosure: Consultant and speaker for Allergan.

Dr. Cavallini is a specialist in plastic surgery, microsurgery, and experimental surgery at CDI Hospital in Milan. Disclosure: Consultant and speaker for Allergan.

Dr. Bertossi is a specialist in maxillofacial surgery, otorhinolaryngology, and facial plastic surgery. He is a professor in the Department of Surgery, Maxillofacial Section, University of Verona. Disclosure: Consultant and speaker for Allergan.

Presented at the 24th World Congress of Dermatology (WCD); June 10-15, 2019; Milan, Italy.